Marc M. Lemaître
Chief Executive Officer at Girindus America, Inc.
Profile
Marc M.
Lemaître is currently the Chief Executive Officer at Girindus America, Inc. and also serves as the Director at Oligonucleotide Therapeutics Society, Inc. Previously, he worked as the CEO, Head-Strategy, Marketing & Sales at Girindus AG i.L.
from 2011 to 2013.
Marc M. Lemaître active positions
| Companies | Position | Start |
|---|---|---|
Girindus America, Inc.
 Girindus America, Inc. Pharmaceuticals: MajorHealth Technology Part of Nitto Denko Corp., Girindus America, Inc. provides oligonucleotide research and production services. The company is based in Cincinnati, OH. The CEO of the company is Marc M. Lemaître. Girindus America was acquired by Nitto Denko Avecia, Inc. from Girindus AG i.L. on January 30, 2013 for $12.60 million. | Chief Executive Officer | - |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | - |
Former positions of Marc M. Lemaître
| Companies | Position | End |
|---|---|---|
| GIRINDUS AG IL | Chief Executive Officer | 10/01/2013 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Girindus AG i.L.
 Girindus AG i.L. Pharmaceuticals: MajorHealth Technology Girindus AG engages in the manufacturing and sale of pharmaceutical and chemical intermediate products. It also offers services including process development, analytical method development, radiolabeling, and manufacturing of active ingredients. The company was founded in 1974 and is headquartered in Hannover, Germany. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
Girindus America, Inc.
Girindus America, Inc. Pharmaceuticals: MajorHealth Technology Part of Nitto Denko Corp., Girindus America, Inc. provides oligonucleotide research and production services. The company is based in Cincinnati, OH. The CEO of the company is Marc M. Lemaître. Girindus America was acquired by Nitto Denko Avecia, Inc. from Girindus AG i.L. on January 30, 2013 for $12.60 million. | Health Technology |
- Stock Market
- Insiders
- Marc M. Lemaître